Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs VanEck Uranium & Nuclear ETF (NLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs VanEck Uranium & Nuclear ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while VanEck Uranium & Nuclear ETF trades at $103.35 (market cap $3.51B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and VanEck Uranium & Nuclear ETF for 8 Days on average.
| IOVA | NLR | |
|---|---|---|
Market Cap | $6.04B | $3.51B |
Volume | 14,805,993 | 414,516 |
Sector | Health | Sector/Thematic |
52-Week High | $14.82 | $164.37 |
52-Week Low | $1.81 | $102.38 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $5.97B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →
